Milurit (Allopurinol)

Allopurinol is a competitive inhibitor of the enzyme xanthine oxidase. By blocking this enzyme, it stops the conversion of purines into uric acid, thereby reducing serum urate concentrations and preventing crystal formation in joints and tissues.

The prescribed dose of Milurit is set by the treating physician based on the patient’s renal function, severity of hyperuricemia, and clinical response. Dosage adjustments are often required for patients with impaired kidney function.

Safety data for allopurinol during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified health professional.

To order Milurit, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to allopurinol is febuxostat, another xanthine oxidase inhibitor. Febuxostat may be preferred in patients with moderate renal impairment, whereas allopurinol is often first‑line because of its long‑standing safety record and lower cost. Choice depends on individual patient factors and physician judgment.

Milurit should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency.

Milurit is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include allopurinol hypersensitivity syndrome, which can involve fever, rash, eosinophilia, and organ dysfunction, as well as severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt medical attention is required if these symptoms appear.

Milurit is contraindicated in patients with known hypersensitivity to allopurinol or any of its components. Caution is also advised for individuals with severe renal or hepatic impairment, and it should be avoided in patients currently receiving azathioprine or mercaptopurine without dose adjustment.